Drug intelligence / Profile preview

Polyvalent Snake Antivenin Serum IP

Development stage: Unknown
Lead developer: Haffkine Bio-Pharmaceutical Corporation
Modality: Antibody-Based Therapeutics
Administration: Intravenous

Overview

Polyvalent Snake Antivenin Serum IP is a lyophilized, enzyme-refined equine immunoglobulin preparation manufactured by Haffkine Bio-Pharmaceutical Corporation Limited. It is a polyvalent antivenom designed to treat snakebite envenoming caused by India's 'big four' venomous snakes: the Indian Cobra (*Naja naja*), Common Krait (*Bungarus caeruleus*), Russell's Viper (*Vipera russelli*), and Saw-scaled Viper (*Echis carinatus*). The product contains equine-derived polyclonal antibodies that provide passive immunization by binding to and neutralizing various venom components, including neurotoxins and hemotoxins, thereby preventing systemic toxicity. It is administered intravenously after reconstitution with sterile water and has been a staple of snakebite treatment in India since its initial production in 1940.

Brand names: Polyvalent Snake Antivenin Serum IP
Other names: ASVSSnake AntiveninAnti-snake venom serumPolyvalent Snake AntiveninHaffkine Anti-snake venom serum

Targets

RVV-X (Russell's viper venom factor X activator)PLA2 (Phospholipase A2 group IID)

Beyond the preview

Go deeper on Polyvalent Snake Antivenin Serum IP.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Polyvalent Snake Antivenin Serum IP.

Explore the full profile